Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 11. Selection of appropriate drugs for glioma patients in the high-risk group. (A–E) OncoPredict showed that the drug scores for rapamycin, dasatinib, 5-fluorouracil and gemcitabine differed between glioma patients in the high- and low-risk groups. ***P < 0.001.